test
- Research Associate, Harvard School of Public Health
- Postdoctoral Fellow, Ragon Institute of MGH, MIT, and Harvard
- PhD, New York University, Pathology- 2016
- BS, Mary Baldwin University, Chemistry-2007
Irvine EB, Nikolov A, Kahn M, Peters JM, Lu R, Sixsmith J, Wallace A, Schenider M, Shin S, Karpinski W, Hsaio JC, van Woundenbergh E, Casadevall A, Bryson BD, Cavacini LA, Grace PS, Fortune SM, Alter GA. Fc-engineered antibodies leverage neutrophils to drive control of Mycobacterium tuberculosis. bioRvx (2022).doi:10.1101/2022.05.01.490220 | View abstract
Grace PS, Gunn BM, Lu LL. Engineering the supernatural: monoclonal antibodies for challenging infectious diseases. Curr Opin Biotechnol. 2022 Dec;78:102818. doi: 10.1016/j.copbio.2022.102818. Epub 2022 Oct 12. PMID: 36242952; PMCID: PMC9612313. | View abstract
Grace PS, Dolatshahi S, Lu LL, Cain A, Palmieri F, Petrone L, Fortune SM, Ottenhoff THM, Lauffenburger DA, Goletti D, Joosten SA, Alter G. Antibody Subclass and Glycosylation Shift Following Effective TB Treatment. Front Immunol. 2021 Jul 5;12:679973. doi: 10.3389/fimmu.2021.679973. PMID: 34290702; PMCID: PMC8287567. | View abstract
Lu LL, Chung AW, Rosebrock TR, Ghebremichael M, Yu WH, Grace PS, Schoen MK, Tafesse F, Martin C, Leung V, Mahan AE, Sips M, Kumar MP, Tedesco J, Robinson H, Tkachenko E, Draghi M, Freedberg KJ, Streeck H, Suscovich TJ, Lauffenburger DA, Restrepo BI, Day C, Fortune SM, Alter G. A Functional Role for Antibodies in Tuberculosis. Cell. 2016 Oct 6;167(2):433-443.e14. doi: 10.1016/j.cell.2016.08.072. Epub 2016 Sep 22. PMID: 27667685; PMCID: PMC5526202. | View abstract
Srivastava S, Grace PS, Ernst JD. Antigen Export Reduces Antigen Presentation and Limits T Cell Control of M. tuberculosis. Cell Host Microbe. 2016 Jan 13;19(1):44-54. doi: 10.1016/j.chom.2015.12.003. PMID: 26764596; PMCID: PMC4715867.
Antibodies are a powerful and adaptive feature of the immune system that can coordinate potent protective responses during infection. Canonically viewed as antigen specific effectors that neutralize extracellular virus via the antigen binding (Fab) domain, the antibody constant (or Fc-) domain also contributes to pathogen control via interactions with complement or Fc receptors (FcR) expressed on immune cells. The Grace lab uses human and mouse models to study antibody mediated immunity in tuberculosis (TB). Our central hypothesis is that antibodies are a key immune feature that can coordinate protective innate and adaptive immunity against TB infection. Through humoral immune profiling and Fc-engineering approaches we aim to:
1. Understand the interaction of antibodies with TB antigens
2. Identify humoral immune correlates in TB patients associated with favorable infection outcomes
3. Define antibody-Fc driven mechanisms that promote bacterial restriction by immune cells
